...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Inhibition of allergen-induced airway inflammation and hyperreactivity by recombinant lactic-acid bacteria
【24h】

Inhibition of allergen-induced airway inflammation and hyperreactivity by recombinant lactic-acid bacteria

机译：重组乳酸菌对变应原诱导的气道炎症和高反应性的抑制

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Recombinant lactic-acid bacteria (LAB) are able to inhibit allergen-specific T-cell responses. In this study, we examined whether oral feeding of recombinant LAB was able to suppress allergen-induced airway inflammation and hyperreactivity (AHR) in a murine model. Animals were intraperitoneally sensitized with Dermatophagoides pteronyssinus group-5 allergen (Der p 5) and orally treated with recombinant LAB containing a plasmid-encoded Der p 5 gene or placebo on day 7 and day 14 for three days consecutively. Twenty-one days after sensitization, mice underwent inhalational challenging. Der p 5-specific immunological responses including changes to specific immunoglobulin G and E (IgE) levels, the presence of cells in the bronchoalveolar lavage fluid (BALF), and AHR were assessed following this inhalational challenge. We demonstrated that oral feeding of recombinant LAB could significantly decrease the synthesis of Der p 5-specific IgE, and AHR. Furthermore, following such treatment, we also noted that both neutrophils and eosinophils had infiltrated the BALF to a significantly lower extent, when compared to the vehicle-treated group. Neither recombinant allergen nor LAB alone was able to suppress allergen-induced immune responses. Our findings suggest that treatment with recombinant LAB at a low dose can suppress allergen-induced airway allergic inflammation, this providing a basis for developing a novel therapeutic method for allergic airway diseases.
机译：重组乳酸菌（LAB）能够抑制过敏原特异性T细胞反应。在这项研究中，我们检查了口服重组LAB能否在鼠模型中抑制变应原诱导的气道炎症和高反应性（AHR）。在第7天和第14天，对动物进行腹膜内用Dermatophagoides pteronyssinus-5过敏原（Der p 5）致敏，并用含有质粒编码Der p 5基因或安慰剂的重组LAB口服治疗，连续三天。致敏后二十一天，小鼠接受了吸入性挑战。在吸入性刺激后，评估了Der p 5特异性免疫反应，包括特定免疫球蛋白G和E（IgE）水平的变化，支气管肺泡灌洗液（BALF）中细胞的存在以及AHR。我们证明口服饲喂重组LAB可以显着降低Der p 5特异性IgE和AHR的合成。此外，在进行此类治疗后，我们还注意到，与溶媒治疗组相比，嗜中性粒细胞和嗜酸性粒细胞都浸润了BALF的程度明显降低。重组变应原和LAB都不能单独抑制变应原诱导的免疫反应。我们的发现表明，低剂量重组LAB的治疗可以抑制变应原诱导的气道变应性炎症，这为开发新的治疗变应性气道疾病的方法提供了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号